Vylor Inc. (VYLR) Stock Price & Analysis
Vylor Inc. (VYLR) closed at USD 73.34 on Thursday, October 15, 2026, down 1.44% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 74.41; the Oct 15, 2026 session ranged USD 73–75.43 on volume of 4,793,849 shares. Market capitalization is $48.94B, with a 52-week range of USD 65–77.39 (NYQ). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VYLR.md
Key facts (VYLR)
- Analysts: Buy (mean 2.13 on a 1–5 scale) (15 analysts), mean target USD 82.62 (range 74–90).
- Total return with dividends: 1Y +7.4% vs S&P 500 +18.1%; 5Y +9.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.5, revenue estimate $918M.
Analysts (VYLR)
Consensus Buy (mean 2.13 on a 1–5 scale), 15 analysts; mean target USD 82.62 (low 74, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | BNP Paribas | Initiated | Neutral | $75 |
| 2026-10-12 | UBS | Initiated | Buy | $89 |
| 2026-10-08 | Goldman Sachs | Initiated | Buy | $87 |
| 2026-10-07 | Keybanc | Initiated | Sector Weight | |
| 2026-10-06 | Oppenheimer | Initiated | Outperform | $82 |
| 2026-10-05 | B of A Securities | Initiated | Buy | $78 |
| 2026-10-05 | Mizuho | Initiated | Outperform | $84 |
| 2026-10-02 | RBC Capital | Initiated | Outperform | $85 |
| 2026-10-02 | Morgan Stanley | Initiated | Overweight | $85 |
| 2026-10-02 | BMO Capital | Initiated | Outperform | $85 |
Total return (dividends reinvested) (VYLR)
| 1Y (from 2026-10-01) | 5Y (from 2026-09-28) | |
|---|---|---|
| Total return | +7.4% | +9.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 53.2% | 34.4% |
| Max drawdown | -4.7% (Oct 2026→Oct 2026) | +0.0% (→) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 73.34 |
|---|---|
| Change | ▼ 1.44% (down) |
| Previous Close | USD 74.41 |
| Open | USD 74.6 |
| Day Range | USD 73 – 75.43 |
| 52-Week Range | USD 65 – 77.39 |
| Volume | 4,793,849 shares |
| Market Cap | $48.94B |
| Exchange | NYQ |
Analyst Ratings (VYLR)
Wall Street analysts rate VYLR "Buy" based on 15 analysts, with a mean price target of USD 82.62 (range USD 74–90), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 82.62 |
| High Target | USD 90 |
| Low Target | USD 74 |
| Buy / Hold / Sell | 11 / 4 / 0 |
Earnings (VYLR)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.5 |
| Revenue Estimate | $918.06M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (VYLR)
| Total Revenue | $17.81B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -1.20% |
| Gross Margin | +49.54% |
| Operating Margin | +30.13% |
| Profit Margin | +5.66% |
| ROE | +4.26% |
| Debt / Equity | 0.19 |
| Current Ratio | 1.52 |
| Total Cash | $2.36B |
| Total Debt | $4.87B |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (VYLR)
Nexqual rates Vylor Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — Revenue +2.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 50%, operating 30% |
| Balance Sheet | Strong — $2.36B cash vs $4.87B debt |
| Cash Flow | Solid — Operating cash flow $1.21B (TTM) |
| Efficiency | Weak — ROE 4%, ROA 4.5% |
Ownership (VYLR)
| Insider Ownership | +0.22% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 667.30M |
| Float | 665.70M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (VYLR)
Vylor Inc. is led by Charles Victor Magro B.Sc. (Chem) (age 55), CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Director | Charles Victor Magro B.Sc. (Chem) (age 55) |
|---|---|
| Chief Financial Officer | David P. Johnson (age 57) |
| Chief Technology Officer | Samuel R. Eathington (age 56) |
| Vice President of Investor Relations | Kimberly Booth |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DMII | Drugs Made In America Acquisiti | USD 10.19 | ▲ 0% |
| CCXI | Churchill Capital Corp XI | USD 11.35 | ▲ 1.7% |
| EVAC | EQV Ventures Acquisition Corp. | USD 10.3 | ▼ 0.1% |
| BCSS | Bain Capital GSS Investment Cor | USD 10.22 | ▼ 0.15% |
| CEPF | Cantor Equity Partners IV, Inc. | USD 10.26 | ▼ 0.24% |
| AEXA | American Exceptionalism Acquisi | USD 10.8 | ▼ 0.92% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt